Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: Neuronal localization and possible function

Neurobiology of Aging

Volumn 34, Issue 5, 2013, Pages 1380-1388

  Wasik, Urszula ^a   Schneider, Gabriela ^a   Mietelska Porowska, Anna ^a   Mazurkiewicz, Marcin ^a   Fabczak, Hanna ^a   Weis, Serge ^b   Zabke, Claudia ^c   Harrington, Charles R ^c   Filipek, Anna ^a   Niewiadomska, Grazyna ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Alzheimer's disease (AD); Amyloidosis; CacyBP SIP; Phosphatase activity; S100A6; Tau mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA TUBULIN; BINDING PROTEIN; CALCYCLIN; CALCYCLIN BINDING PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRESENILIN 1; SIAH 1 INTERACTING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN TISSUE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PARAHIPPOCAMPAL GYRUS; PERIKARYON; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TAUOPATHY; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; CALCIUM-BINDING PROTEINS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; NUCLEAR PROTEINS; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84873475745     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.11.007     Document Type: Article

References (50)

1. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging 1997, 18(4 suppl):S1-S2.
2. Baas P.W., Qiang L. Neuronal microtubules: when the MAP is the roadblock. Trends Cell. Biol. 2005, 15:183-187.
3. Bhattacharya S., Lee Y.T., Michowski W., Jastrzebska B., Filipek A., Kuznicki J., Chazin W. The modular structure of SIP facilitates its role in stabilizing multiprotein assemblies. Biochemistry 2005, 44:9462-9471.
4. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 1985, 101:1371-1378.
5. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Braak H., Braak E. Staging of Alzheimer-related cortical destruction. Int. Psychogeriatr. 1997, 9(suppl 1):257-261.
8. Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl. 1998, 53:127-140.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
10. Braithwaite S.P., Stock J.B., Lombroso P.J., Nairn A.C. Protein phosphatases and Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 2012, 106:343-379.
11. Brandt R., Hundelt M., Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Bichim. Biophys. Acta 2005, 1739:331-354.
12. Dickson D.W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 1997, 18:S21-S26.
13. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
14. 2+ dysfunction in neurodegenerative disorders: Alzheimer's disease. Biofactors 2011, 37:189-196.
15. Filipek A., Jastrzebska B., Nowotny M., Kuznicki J. CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J. Biol. Chem. 2002, 277:28848-28852.
16. 2+-dependent translocation of the calcyclin binding protein in neurons and neuroblastoma cells. J. Biol. Chem. 2002, 277:21103-21109.
17. Filipek A., Kuźnicki J. Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin. J. Neurochem. 1998, 70:793-798.
18. Filipek A., Schneider G., Mietelska A., Figiel I., Niewiadomska G. Age-dependent changes in neuronal distribution of CacyBP/SIP: comparison to tubulin and the tau protein. J. Neural Transm. 2008, 115:1257-1264.
19. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2008, Academic Press, New York. third ed.
20. Gong C.X., Liu F., Grundke-Iqbal I., Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Trans. 2005, 112:813-838.
21. Harrington C.R. The molecular pathology of Alzheimer's disease. Neuroimaging Clin. N. Am. 2012, 22:11-22.
22. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenber T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
23. Jastrzebska B., Filipek A., Nowicka D., Kaczmarek L., Kuznicki J. Calcyclin (S100A6) binding protein (CacyBP) is highly expressed in brain neurons. J. Histochem. Cytochem. 2000, 48:1195-1202.
24. Kilanczyk E., Filipek S., Filipek A. ERK1/2 is dephosphorylated by a novel phosphatase - CacyBP/SIP. Biochem. Biophys. Res. Commun. 2011, 404:179-183.
25. Kilanczyk E., Filipek S., Jastrzebska B., Filipek A. CacyBP/SIP binds ERK1/2 and affects transcriptional activity of Elk-1. Biochem. Biophys. Res. Commun. 2009, 380:54-59.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
27. Lim F., Hernández F., Lucas J.J., Gómez-Ramos P., Morán M.A., Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell Neurosci. 2001, 18:702-714.
28. Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. J. Biol. Chem. 2005, 280:1790-1796.
29. Matsuzawa S., Reed J.C. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell. 2001, 7:915-926.
30. Mayeux R. Clinical practice. Early Alzheimer's disease. N. Engl. J Med. 2010, 362:2194-2201. [erratum in N. Engl. J. Med. 2010;363:1190].
31. Mirra S.S., Hart M.N., Terry R.D. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 1993, 117:132-144.
32. Niewiadomska G., Baksalerska-Pazera M., Lenarcik I., Riedel G. Compartmental protein expression of Tau, GSK-3beta and TrkA in cholinergic neurons of aged rats. J. Neural Transm. 2006, 113:1733-1746.
33. Niewiadomska G., Baksalerska-Pazera M., Riedel G. Altered cellular distribution of phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats. Ann. N. Y. Acad. Sci. 2005, 1048:287-295.
34. Nizzari M., Barbieri F., Gentile M.T., Passarella D., Caorsi C., Diaspro A., Taglialatela M., Pagano A., Colucci-D'Amato L., Florio T., Russo C. Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein tau. J. Alzheimer Dis. 2012, 29:211-227.
35. Osiecka K.M., Nieznanska H., Skowronek K.J., Jozwiak J., Nieznanski K. Tau inhibits tubulin oligomerization induced by prion protein. Biochim. Biophys. Acta 2011, 1813:1845-1853.
36. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
37. Rahman A., Grundke-Iqbal I., Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem. Res. 2005, 30:277-287.
38. Rahman A., Grundke-Iqbal I., Iqbal K. PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J. Neural Transm. 2005, 113:219-230.
39. Schneider G., Filipek A. S100A6 binding protein and Siah-1 interacting protein (CacyBP/SIP): spotlight on properties and cellular function. Amino Acids 2011, 41:773-780.
40. Schneider G., Nieznanski K., Jozwiak J., Slomnicki L.P., Redowicz M.J., Filipek A. Tubulin binding protein, CacyBP/SIP, induces actin polymerization and may link actin and tubulin cytoskeletons. Biochim. Biophys. Acta 2010, 1803:1308-1317.
41. Schneider G., Nieznanski K., Kilanczyk E., Bieganowski P., Kuznicki J., Filipek A. CacyBP/SIP interacts with tubulin in neuroblastoma NB2a cells and induces formation of globular tubulin assemblies. Biochim. Biophys. Acta 2007, 1773:1628-1636.
42. Spiechowicz M., Zylicz A., Bieganowski P., Kuznicki J., Filipek A. Hsp70 is a new target of Sgt1-an interaction modulated by S100A6. Biochem. Biophys. Res. Commun. 2007, 357:1148-1153.
43. Tatebayashi Y., Miyasaka T., Chui D.-H., Akagi T., Mishima K.I., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U. S. A 2002, 99:13896-13901.
44. Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K. Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett. 2005, 579:363-372.
45. Wischik C.M., Edwards P.C., Lai R.Y.K., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Nat. Acad. Sci. U. S. A 1996, 93:11213-11218.
46. Wischik C.M., Novak M., Thøgersen H.C., Edwards P.C., Runswick M.J., Jakes R., Walker J.E., Milstein C., Roth M., Klug A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 1988, 85:4506-4510.
47. Yamaguchi F., Umeda Y., Shimamoto S., Tsuchiya M., Tokumitsu H., Tokuda M., Kobayashi R. S100 proteins modulate protein phosphatase 5 function: a link between Ca2+ signal transduction and protein dephosphorylation. J. Biol. Chem. 2012, 287:13787-13798.
48. Yan J., Sun X.B., Wang H.Q., Zhao H., Zhao X.Y., Xu Y.X., Guo J.C., Zhu C.Q. Chronicrestraint stress alters the expression and distribution of phosphorylated tau and MAP2 in cortex and hippocampus of rat brain. Brain Res. 2010, 1347:132-141.
49. Zabke C., Dietze S., Stamer K., Rickard J.E., Harrington C.R., Theuring F., Seng K.M., Wischik C.M. P1-054: Early and advanced stages of Tau aggregation in transgenic mouse models. Alzheimer' Dement. 2008, 4:T221-T222.
50. Zhang B., Higuchi M., Yoshiyama Y., Ishihara T., Forman M.S., Martinez D., Joyce S., Trojanowski J.Q., Lee V.M. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 2004, 24:4657-4667.